secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001213900-24-099094
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies Q3 net loss $2.9M; Phase 2b osteosarcoma data due Dec 2024
-----------------------------------------------------------------------

- Net operating loss $2.875M in Q3 2024 vs $2.006M in Q3 2023; EPS -$0.18 vs -$0.38.
- Completed dosing all 41 patients in Phase 2b trial of OST-HER2 in resected recurrent osteosarcoma.
- Topline Phase 2b data expected December 2024; seeking FDA Breakthrough Therapy designation.
- Company completed IPO in Q3 2024; pre-revenue with future revenue expected from priority review voucher.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390024099094/0001213900-24-099094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390024099094/ea0221417-8k_osthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-099094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer